WO2013153155A3 - The use of mirna particles and mirna antagomir for diagnostics, prevention and treatment of multiple sclerosis - Google Patents

The use of mirna particles and mirna antagomir for diagnostics, prevention and treatment of multiple sclerosis Download PDF

Info

Publication number
WO2013153155A3
WO2013153155A3 PCT/EP2013/057585 EP2013057585W WO2013153155A3 WO 2013153155 A3 WO2013153155 A3 WO 2013153155A3 EP 2013057585 W EP2013057585 W EP 2013057585W WO 2013153155 A3 WO2013153155 A3 WO 2013153155A3
Authority
WO
WIPO (PCT)
Prior art keywords
mirna
prevention
treatment
multiple sclerosis
diagnostics
Prior art date
Application number
PCT/EP2013/057585
Other languages
French (fr)
Other versions
WO2013153155A2 (en
Inventor
Marcin MYCKO
Krzysztof Selmaj
Original Assignee
Mycko Marcin
Krzysztof Selmaj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mycko Marcin, Krzysztof Selmaj filed Critical Mycko Marcin
Publication of WO2013153155A2 publication Critical patent/WO2013153155A2/en
Publication of WO2013153155A3 publication Critical patent/WO2013153155A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The object of the present invention is the use of the noncoding RNA particles (microRNA) and antagomirs for microRNA in medicine, in particular for prevention and treatment of autoimmune diseases, in particularly for multiple sclerosis.
PCT/EP2013/057585 2012-04-11 2013-04-11 The use of mirna particles and mirna antagomir for diagnostics, prevention and treatment of multiple sclerosis WO2013153155A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL398796A PL398796A1 (en) 2012-04-11 2012-04-11 The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis
PLP398796 2012-04-11

Publications (2)

Publication Number Publication Date
WO2013153155A2 WO2013153155A2 (en) 2013-10-17
WO2013153155A3 true WO2013153155A3 (en) 2013-12-05

Family

ID=48669859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/057585 WO2013153155A2 (en) 2012-04-11 2013-04-11 The use of mirna particles and mirna antagomir for diagnostics, prevention and treatment of multiple sclerosis

Country Status (2)

Country Link
PL (1) PL398796A1 (en)
WO (1) WO2013153155A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111777667B (en) * 2020-07-10 2022-09-09 上海交通大学医学院 Small peptide and application thereof in preparation of immunoregulation medicine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003989A1 (en) * 2009-07-08 2011-01-13 Administración General De La Comunidad Autónoma De Euskadi Methods for the diagnosis of multiple sclerosis based on its microrna expression profiling
WO2012037043A2 (en) * 2010-09-13 2012-03-22 California Institute Of Technolgoy Treatment of autoimmune inflammation using mir-155
WO2013013165A2 (en) * 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003989A1 (en) * 2009-07-08 2011-01-13 Administración General De La Comunidad Autónoma De Euskadi Methods for the diagnosis of multiple sclerosis based on its microrna expression profiling
WO2012037043A2 (en) * 2010-09-13 2012-03-22 California Institute Of Technolgoy Treatment of autoimmune inflammation using mir-155
WO2013013165A2 (en) * 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANGSHENG DU ET AL: "MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis", NATURE IMMUNOLOGY, vol. 10, no. 12, 18 October 2009 (2009-10-18), pages 1252 - 1259, XP055081713, ISSN: 1529-2908, DOI: 10.1038/ni.1798 *
G. MURUGAIYAN ET AL: "Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis", THE JOURNAL OF IMMUNOLOGY, vol. 187, no. 5, 25 July 2011 (2011-07-25), pages 2213 - 2221, XP055082209, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1003952 *
JUNKER ANDREAS ET AL: "MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 132, no. 12, 1 December 2009 (2009-12-01), pages 3342 - 3352, XP008125500, ISSN: 0006-8950, [retrieved on 20091201], DOI: 10.1093/BRAIN/AWP300 *
M. P. MYCKO ET AL: "PNAS Plus: microRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 20, 15 May 2012 (2012-05-15), pages E1248 - E1257, XP055081763, ISSN: 0027-8424, DOI: 10.1073/pnas.1114325109 *
MYCKO MARCIN P ET AL: "MicroRNA301a Downregulation Attenuates Animal Model of MS", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 76, no. 9, Supplemet 4, 1 March 2011 (2011-03-01), pages A652, XP008165096, ISSN: 0028-3878 *
RYAN M. O'CONNELL ET AL: "MicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell Development", IMMUNITY, vol. 33, no. 4, 30 September 2010 (2010-09-30), pages 607 - 619, XP055081715, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2010.09.009 *

Also Published As

Publication number Publication date
WO2013153155A2 (en) 2013-10-17
PL398796A1 (en) 2013-10-14

Similar Documents

Publication Publication Date Title
IL278396A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
IL263843B (en) Antisense compounds comprising antisense oligonucleotide complementary to a nucleic acid transcript and compositions comprising the same for the treatment of metabolic related diseases
HK1212376A1 (en) Rna-guided human genome engineering rna
WO2013018060A3 (en) Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2014036219A3 (en) Methods and compositions for treatment of a genetic condition
EP2883886A4 (en) Modified ethylene-(vinyl alcohol) copolymer, method for producing same, and use of same
MY172292A (en) Vectors and sequences for the treatment of diseases
WO2014007620A3 (en) Oligonucleotide for the treatment of muscular dystrophy patients
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
WO2012125987A3 (en) Delivery system
PL2820051T3 (en) Derivates based on hyaluronic acid, capable of forming hydrogels, method of preparation thereof, hydrogels based on said derivatives, method of preparation thereof and use
PL2882779T3 (en) Hyaluronic acid derivative, method of preparation thereof, method of modification thereof and use thereof
EP3316894A4 (en) Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
MX2016016992A (en) Aptamers specific for tlr-4 and uses thereof.
EP3104862A4 (en) Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith
HK1215173A1 (en) Methods of treating s. aureus-associated diseases
EP3364984A4 (en) Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
HK1210025A1 (en) Method and agent for the treatment and prophylaxis of diseases caused by ()rna-containing viruses ()rna
WO2013124807A3 (en) Oligonucleotides for modulating gene expression and uses thereof
WO2015012541A3 (en) Kit for early diagnosis of alzheimer's dementia
WO2013072933A3 (en) Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2015007871A3 (en) Micrornas and autoimmune-immune mediated inflammatory disease
EP2931746A4 (en) Methods and compositions for the specific inhibition of ckap5 by double-stranded rna

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13730123

Country of ref document: EP

Kind code of ref document: A2